Ellagic Acid-Cyclodextrin Complexes for the Treatment of Oral Candidiasis

Author(s)

Sampaio, Aline da Graca ^[1] ; Gontijo, Aline Vidal Lacerda ^[1] ; Lima, Gabriela de Morais Gouvea ^[1] ; de Oliveira, Maria Alcioneia Carvalho ^[1] ; Lepesqueur, Laura Soares Souto ^{[1, 2]} ; Koga-Ito, Cristiane Yumi ^{[1, 3]}

Affiliation

^[1] Sao Paulo State Univ, UNESP, Oral Biopathol Grad Program, Sao Jose Campos Inst Sci & Technol, BR-12245000 Sao Paulo - Brazil

^[2] Univ Santo Amaro, Sch Dent, BR-04743030 Sao Paulo - Brazil

^[3] Sao Paulo State Univ, UNESP, Sao Jose Campos Inst Sci & Technol, Dept Environm Engn, BR-12247016 Sao Paulo - Brazil

• Document type: Journal article
• Source: Molecules; v. 26, n. 2 JAN 2021.
• Web of Science Citations: 1

Abstract

The increase in the prevalence of fungal infections worldwide and the rise in the occurrence of antifungal resistance suggest that new research to discover antifungal molecules is needed. The aim of this study was to evaluate the potential use of ellagic acid-cyclodextrin complexes (EA/HP-beta-CD) for the treatment of oral candidiasis. First, the effect of EA/HP-beta-CD on C. albicans planktonic cells and biofilms was evaluated. Then, the cytotoxicity of the effective concentration was studied to ensure safety of in vivo testing. Finally, the in vivo effectiveness was determined by using a murine model of induced oral candidiasis. Data was statistically analyzed. The minimal inhibitory concentration of EA/HP-beta-CD was 25 mu g/mL and a concentration of 10 times MIC (250 mu g/mL) showed an inhibitory effect on C. albicans 48 h-biofilms. The complex at concentration 250 mu g/mL was classified as slightly cytotoxic. In vivo experiments showed a reduction in fungal epithelial invasion after treatment with EA/HP-beta-CD for 24 h and 96 h when compared to the negative control. In conclusion, the results demonstrated that EA/HP-beta-CD has antifungal and anti-inflammatory effects, reducing the invasive capacity of C. albicans, which suggests that EA/HP-beta-CD may be a promising alternative for the treatment of oral candidiasis. (AU)

• FAPESP's process: 16/07196-6 - Prospection of innovative therapeutic alternatives for infectious diseases with relevance in Dentistry: low temperature atmospheric pressure plasma and nanoencapsulate of bioactive substance
• Grantee: Cristiane Yumi Koga Ito
• Support Opportunities: Regular Research Grants